[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614318":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":25,"centralContacts":30,"locations":39,"responsibleParty":51,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":10,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":10,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Mahidol University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tranexamic acid group",null,"Patients received tranexamic acid after postpartum hemorrhage",[13],"Drug: Tranexamic acid",{"label":15,"type":10,"description":16,"interventionNames":10},"Non tranexamic acid group","Patients did not receive tranexamic acid after postpartum hemorrhage",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Tranexamic acid","The number of patients received tranexamic acid after postpartum hemorrhage",[9],[24],"TXA",[26],{"name":27,"affiliation":28,"role":29},"Patchareya Nivatpumin, M.D.","Siriraj Hospital","PRINCIPAL_INVESTIGATOR",[31,35],{"name":27,"role":32,"phone":33,"phoneExt":10,"email":34},"CONTACT","+66896662187","patcahreya.niv@mahidol.ac.th",{"name":36,"role":32,"phone":37,"phoneExt":10,"email":38},"Premyuda Matangkarat, M.D.","+66959472598","premyuda.mat@mahidol.ac.th",[40],{"facility":28,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":10,"geoPoint":10,"contacts":47},"RECRUITING","Bangkoknoi","Bangkok","10700","Thailand","TH",[48,50],{"name":27,"role":32,"phone":33,"phoneExt":10,"email":49},"patchareya.niv@mahidol.ac.th",{"name":36,"role":32,"phone":37,"phoneExt":10,"email":38},{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100614318","trends-in-the-administration-of-tranexamic-acid-for-postpartum-hemorrhage-100614318",false,"NCT07278037","Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage","A Retrospective Analysis of the Longitudinal Pattern of Tranexamic Acid Administration in Parturients Undergoing Cesarean Delivery Complicated by Postpartum Hemorrhage","Inclusion Criteria:\n\n* 1\\. Patients underwent cesarean delivery with primary postpartum hemorrhage\n\nExclusion Criteria:\n\n1. Gestational age at less than 24 weeks\n2. Absence of the anesthetic record\n3. Received tranexamic acid in the antepartum period\n4. Blood loss less than 1,000 ml","FEMALE",{"count":62,"type":63},648,"ESTIMATED","OBSERVATIONAL","Postpartum hemorrhage (PPH) is the global leading cause of maternal death, with 20-30% of maternal deaths in Thailand linked to hemorrhage. The WOMAN Trial (2017) provided strong evidence that administering tranexamic acid (TXA)within three hours of bleeding onset lowered PPH-related mortality by 31%. Consequently, the World Health Organization (WHO) updated its guidelines, recommending TXA as part of the standard treatment package for all PPH cases. Following this, the use of TXA has been widely adopted globally and increased in Thailand. A recent study at a major Thai university hospital observed a significant increase in TXA administration after 2017. The current study aims to further analyze the recent growth rate of TXA use and its impact on obstetric and perinatal outcomes during cesarean deliveries with PPH.",[67,68,69,70],"Postpartum Hemorrhage","Delivery Complication","Cesarean Section Complications","Perinatal Problems",[72,73,74,75],"cesarean delivery","complications","postpartum hemorrhage","tranexamic acid","2025-12-16",{"date":78,"type":79},"2025-12-22","ACTUAL",{"date":81,"type":79},"2025-12-01",{"date":83,"type":63},"2026-09-30",{"name":5,"class":6},1]